. Author manuscript; available in PMC: 2011 May 26.

Published in final edited form as: Hum Genet. 2011 Jan 28;129(3):345–349. doi: 10.1007/s00439-011-0950-8

Table 1.

Incidence of T36M change in the ARPKD cohort, a cohort with proven colorectal carcinoma and a clinic-based control group without a history of colonic carcinoma.

	ARPKD cohort	Controls Group 1	Colorectal Carcinoma Group 1
36M alleles	24	6	0
Total alleles (subjects)	183 (92)	3202 (1601)	3684 (1842)
36M rate per allele (95% CI)	13.1% (8.9–18.8%)	0.19% (0.088–0.41%)	0% (0.0007–0.1%)
36M rate per subject	26.1%	0.37%^**	0.0%^**

	Controls Group2	Colorectal Carcinoma group 2	Control Combined	Colorectal Combined
36M alleles	9	1	15	1
Total alleles(subject)	4004 (2002)	3850 (1925)	7206 (3603)	7534 (3767)
36M rate per allele (95% CI)	0.22% (0.11–0.45%)	0.026% (1.35e⁻³–0.17%)	0.21% (0.12–0.35%)	0.013% (6.9e⁻⁴–0.086%)
36M rate per subject	0.45%^*	0.05%^*	0.42%^***	0.03%^***

^**

The difference between the control and cancer sample is significant at p=0.01 (Fisher's exact test).

The difference between the control and cancer sample is significant at p=0.02 (Fisher's exact test).

^***

The difference between the combined control and cancer sample is significant at p=0.0002 (Fisher's exact test). Odd ratio =0.072, 95% CI: 0.003–0.36.